skip to Main Content
California’s Legalization Bill Brings Mixed Feelings To The Industry

A potent tension is disturbing the aromatic green fields and verdant centers of marijuana commerce in California as pot farmers and weed merchants brood over a future that is even more uncertain as the corporate world cozies up to the smokable herb.
A ballot measure that would legalize recreational pot has divided people who produce the mind-altering and medicinal plant, particularly the small growers in Humboldt, Mendocino and Trinity counties, the cannabis mecca known as the Emerald Triangle.

Some in the industry believe legitimacy would boost their bottom line, but others fear the Adult Use of Marijuana Act, labeled Proposition 64, would allow venture capitalists to drive out the small farmers who provided the troubled former timber towns on the North Coast with an economic engine and made California the weed capital of the world. [Read more at San Francisco Chronicle]

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

POSaBIT Buys Suite of Platforms (Leaf Data Systems, MJ Platform and Ample Organics) from Embattled Akerna Corp.

POSaBIT, the cannabis point-of-sale (POS) and payments software company, this morning announced its planned acquisition of  MJ Platform (MJ Freeway), Leaf Data Systems, and Ample Organics from embattled software company…

New York State now has 66 licensed cannabis retailers

New York marijuana regulators on Wednesday approved dozens of conditional adult-use dispensary licenses in a session during which members also discussed adopting bylaws for how the board runs meetings and makes decisions.…

FDA Says “No” to CBD Foods and Dietary Supplements

By Griffin Thorne, Attorney at Harris Bricken Since the passage of the 2018 Farm Bill, the hemp CBD industry has been eagerly awaiting FDA CBD regulations. In that time, FDA…

FDA finalizes guidance on cannabis clinical research

The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds without…

More Categories

Back To Top
×Close search